Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−6.50 USD
−5.57 M USD
184.00 K USD
648.63 K
About Titan Pharmaceuticals, Inc.
Sector
CEO
Brynner Chiam
Headquarters
South San Francisco
Website
Founded
1992
FIGI
BBG000BTGSY7
Titan Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, proNeura. Its lead product is probuphine, a buprenorphine implant for the maintenance treatment of opioid addiction. The company was founded by Louis R. Bucalo on February 7, 1992 and is headquartered in South San Francisco, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TTNP is 3.93 USD — it has decreased by −1.39% in the past 24 hours. Watch Titan Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Titan Pharmaceuticals, Inc. stocks are traded under the ticker TTNP.
TTNP stock has fallen by −17.79% compared to the previous week, the month change is a −23.48% fall, over the last year Titan Pharmaceuticals, Inc. has showed a −48.08% decrease.
TTNP reached its all-time high on Sep 29, 2000 with the price of 1,293,069.29 USD, and its all-time low was 3.57 USD and was reached on Oct 28, 2024. View more price dynamics on TTNP chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TTNP stock is 22.60% volatile and has beta coefficient of −1.25. Track Titan Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Titan Pharmaceuticals, Inc. there?
Today Titan Pharmaceuticals, Inc. has the market capitalization of 3.34 M, it has decreased by −8.52% over the last week.
Yes, you can track Titan Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Titan Pharmaceuticals, Inc. is going to release the next earnings report on Nov 21, 2024. Keep track of upcoming events with our Earnings Calendar.
TTNP net income for the last quarter is −2.09 M USD, while the quarter before that showed −1.06 M USD of net income which accounts for −97.45% change. Track more Titan Pharmaceuticals, Inc. financial stats to get the full picture.
No, TTNP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 4.00 employees. See our rating of the largest employees — is Titan Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Titan Pharmaceuticals, Inc. EBITDA is −7.09 M USD, and current EBITDA margin is −3.89 K%. See more stats in Titan Pharmaceuticals, Inc. financial statements.
Like other stocks, TTNP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Titan Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Titan Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Titan Pharmaceuticals, Inc. stock shows the sell signal. See more of Titan Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.